Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy

29.03.2007
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans.

The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication. This restriction is due to theoretical safety concerns associated with small EKG changes noted in patients taking ranolazine.

Accordingly, the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes (MERLIN TIMI-36) study, presented today at the American College of Cardiology’s 56th Annual Scientific Session, had the dual objectives to provide new long-term safety data on ranolazine in a high-risk population of patients with acute coronary syndromes (ACS) and to study the drug’s efficacy in a broad population of people with unstable angina due to ACS. ACC.07 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists from around the world to further breakthroughs in cardiovascular medicine.

The efficacy data showed that ranolazine did not produce a statistically significant reduction in the composite endpoint of cardiovascular death, heart attack and recurrent ischemia (the primary efficacy endpoint of the study), but did show a statistically significant reduction in recurrent ischemia alone. The data showed no adverse trend in death or arrhythmia in patients receiving ranolazine.

Ranolazine is a novel anti-ischemic agent that, unlike other classes of anti-anginal therapy, does not significantly reduce heart rate or blood pressure. The MERLIN TIMI-36 study evaluated the safety and efficacy of ranolazine in the short- and long-term treatment of patients with non-ST elevation ACS.

The placebo-controlled, double-blind study enrolled 6,560 ACS patients at 440 sites in 17 countries whose EKG tests showed no ST elevation, indicating some artery blockage due to a blood clot, but not total blockage of the artery. All were treated with standard of care, including aspirin, beta-blockers, an oral anti-platelet, and anti-coagulant; many also had angioplasty or other coronary surgical procedures. The study group received 200 mg of ranolazine intravenously over one hour, followed by an 80 mg per hour infusion for up to 96 hours. The study group then took 1000 mg of oral ranolazine twice daily for approximately 12 months. The control group underwent the same intravenous and oral treatment regimen, but with placebo.

"In the high risk population enrolled in MERLIN TIMI-36, ranolazine appeared to be safe. In addition, the reduction in recurrent ischemia we observed with ranolazine provides new information regarding efficacy of ranolazine as an anti-anginal in a much broader population than has previously been studied." said David Morrow, M.D., MPH, of Brigham & Women’s Hospital at Harvard Medical School and lead author of the study.

Dr. Morrow will present the results of "Evaluation of a Novel Anti-Ischemic Agent in Acute Coronary Syndromes: The Primary Results of the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 Trial" on Tuesday, March 27 at 8:50 a.m. in Hall A.

Leslie Humbel | EurekAlert!
Further information:
http://www.acc.org

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>